tbuckley/cabot-search huggingface dataset:
Lrig1+ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach
Authors: Eunyoung Choi, Tyler L Lantz, Gregory Vlacich, Theresa M Keeley, Linda C Samuelson, Robert J Coffey, James R Goldenring, Anne E Powell
Journal: Gut (2017)

Objective Lrig1 is a marker of proliferative and quiescent stem cells in the skin and intestine. We examined whether Lrig1-expressing cells are long-lived gastric progenitors in gastric glands in the mouse stomach. We also investigated how the Lrig1-expressing progenitor cells contribute to the regeneration of normal gastric mucosa by lineage commitment to parietal cells after acute gastric injury in mice. Design We performed lineage labelling using Lrig1-CreERT2/+;R26R-YFP/+ (Lrig1/YFP) or R26R-LacZ/+ (Lrig1/LacZ) mice to examine whether the Lrig1-YFP-marked cells are gastric progenitor cells. We studied whether Lrig1-YFP-marked cells give rise to normal gastric lineage cells in damaged mucosa using Lrig1/YFP mice after treatment with DMP-777 to induce acute injury. We also studied Lrig1- CreERT2/CreERT2 (Lrig1 knockout) mice to examine whether the Lrig1 protein is required for regeneration of gastric corpus mucosa after acute injury. Results Lrig1-YFP-marked cells give rise to gastric lineage epithelial cells both in the gastric corpus and antrum, in contrast to published results that Lgr5 only marks progenitor cells within the gastric antrum. Lrig1-YFP-marked cells contribute to replacement of damaged gastric oxyntic glands during the recovery phase after acute oxyntic atrophy in the gastric corpus. Lrig1 null mice recovered normally from acute gastric mucosal injury indicating that Lrig1 protein is not required for lineage differentiation. Lrig1+ isthmal progenitor cells did not contribute to transdifferentiating chief cell lineages after acute oxyntic atrophy. Conclusions Lrig1 marks gastric corpus epithelial progenitor cells capable of repopulating the damaged oxyntic mucosa by differentiating into normal gastric lineage cells in mouse stomach.
The Coronary Drug Project
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The influence of hypoxia in promoting malignant progression in prostate cancer cells.
Authors: Karl Butterworth, Helen O. McCarthy, Tracy Robson, Stephanie McKeown
Journal: Cancer Research (2004)

3414   Malignant progression of prostate tumors is characterized by the development of a hormone refractory phenotype. There is increasing evidence that tumor hypoxia can influence this process in many tumour types including prostate. The aim of this study was to investigate whether growth in hypoxic conditions would lead to the emergence of a hormone refractory phenotype in the LNCaP cells. These prostate tumor cells exhibit androgen-dependent growth and express prostate specific androgen (PSA). Initially we investigated the hypoxia tolerance of log phase LNCaP cells in a hypoxic atmosphere (0.1% oxygen: 94.9% nitrogen: 5% CO 2 ) using a hypoxic work station (Ruskinn Technologies, UK). LNCaP cells were surprisingly hypoxia resistant. Exposure for 24 hours at 0.1% oxygen caused almost no loss of cells. Even at 48 hours the loss was only 50% and after 6 days the cell numbers had recovered to the plateau level of the untreated cells. Exposure for 72 hours was effective at killing all the cells. To investigate the effect of intermittent hypoxia on LNCaP growth, log phase cells were grown in the 0.1% oxygen atmosphere initially for 48 hours, every week for 6 weeks. The cells then became noticeably more hypoxia tolerant and exposure to 0.1% hypoxia was increased to 72 hours per week. The process was repeated for 6 months when an increase in growth rate was noted. These cells were harvested and designated LNCaP-H1. The cells were implanted into a female SCID mouse and were capable of forming a tumour, suggesting that the cell line had become androgen independent. Implanted parental cells did not form tumours. When compared with the parental cell line the LNCaP-H1 cells exhibit features which are in line with a more malignant hormone refractory phenotype. Our model suggests that hypoxia can influence malignant progression in prostate cancer cells and more importantly we have shown that the selected cells are androgen-independent; the LNCaP-H1 cells can grow successfully in charcoal stripped medium. We hypothesize that low oxygen tension may select for a more aggressive phenotype, provide a mutagenic microenvironment for cellular dedifferentiation or trigger the expression of stress response genes to facilitate malignant progression.
Incomplete non-small-cell lung cancer (NSCLC) resections in the National Cancer Data Base (NCDB): Predictors, prognosis and value of adjuvant therapy.
Authors: Raymond U Osarogiagbon, Chun Chieh Lin, Matthew Smeltzer, Ahmedin Jemal
Journal: Journal of Clinical Oncology (2015)

7527 Background: Data are limited on the expected rate and survival impact of incomplete NSCLC resections, and the value of postoperative adjuvant therapy in this situation. Methods: We analyzed surgically treated stage I-IIIA NSCLC patients in the NCDB from 2004 to 2011 for clinical, sociodemographic and institutional factors associated with margin-positive resection using multivariate logistic regression models. We compared survival of patients with and without positive margins using proportional hazards (PH) models; and the impact of postoperative adjuvant therapy evaluated with multivariate PH models. Results: Of 113,007 resections over 8 years, 5338 (4.72%) had positive margins. Black race, age-based Medicare insurance and urban residence (p < .01) were associated with increased adjusted odds ratio (aOR) of resection with positive margins. Squamous histology, high tumor grade, tumor location in the main bronchus, and advancing pathologic stage were clinical factors associated with higher aOR (p < .001). Surgery performed at Community Cancer Programs, institutions with high proportions of underinsured patients, institutions at lower cancer resection volume quartiles, also had increased aOR (p < .01). The stage-adjusted 5-year survival rate of margin negative vs positive patients was 59% and 40%, respectively (p < .0001). After adjustment for stage and other significant factors, postoperative adjuvant therapy was associated with a lower 5-year mortality risk: adjusted hazard ratio 0.75 (p < .0001) for chemotherapy; 0.86 (p < .002) for radiotherapy; 0.75 (p < .0001) for chemoradiotherapy. Conclusions: Black race, urban residence, and certain facility characteristics (e.g., low resection volume and high percentage of underinsured patients) were independently associated with incomplete resection. Margin involvement significantly impairs survival after lung cancer resection, irrespective of stage. Contributory intra-institutional provider practices should be identified, to minimize this outcome disparity. Postoperative adjuvant therapy mitigates the mortality risk independently of stage, and should be offered to all patients.
蛍光/光音響/超音波イメージング誘導腫瘍光線力学療法を強化するための酸素生成ハイブリッドナノ粒子【Powered by NICT】
Authors: Gao Shi, Wang Guohao, Qin Zainen, Wang Xiangyu, Zhao Guoqing, Ma Qingjie, Zhu Lei
Journal: Biomaterials (2017)
Erratum. Gene-Environment Interactions of Circadian-Related Genes for Cardiometabolic Traits. Diabetes Care 2015;38:1456–1466
Authors: Hassan S. Dashti, Jack L. Follis, Caren E. Smith, Toshiko Tanaka, Marta Garaulet, Daniel J. Gottlieb, Adela Hruby, Paul F. Jacques, Jessica C. Kiefte-de Jong, Stefania Lamon-Fava, Frank A.J.L. Scheer, Traci M. Bartz, Leena Kovanen, Mary K. Wojczynski, Alexis C. Frazier-Wood, Tarunveer S. Ahluwalia, Mia-Maria Perälä, Anna Jonsson, Taulant Muka, Ioanna P. Kalafati, Vera Mikkilä, José M. Ordovás
Journal: Diabetes Care (2017)

In the above-mentioned article, the names listed in the appendix should have all been cited as authors of the article. The byline, the footnotes, and the appendix all have been corrected. The Author contributions section has been updated and added to the Supplementary Data online.

Author …
FRI0149 Does thyroxin substitution predict non-response to methotrexate in early ra?
Authors: K Waldenlind, S Saevarsdottir, C Bengtsson, J Askling
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Response to treatment varies widely between RA-patients. Our means to predict disease course and treatment response is limited, leading to substantial over- as well as under- treatment. Whereas female gender and smoking have been identified as predictors of non-response, the impact of autoimmune co-morbidities remains largely unknown. Autoimmune thyroid disease (AITD) is one of the most frequent autoimmune diseases in the population. AITD is more prevalent in RA-patients and has also been identified as a risk factor for RA. AITD can be readily identified via thyroxin substitution. We aimed at assessing the impact of prevalent AITD in relation to 3- and 6-month EULAR response to methotrexate in early RA. <h3>Objectives</h3> To investigate whether thyroxin substitution impacts response to methotrexate as the first-line therapy in RA. <h3>Methods</h3> We identified patients with incident RA (symptom duration &lt;1 year), included in the Swedish Rheumatology Quality Register, July 2006 through 2015 (n=7009). All patients starting treatment with methotrexate and who had a follow-up visit at 3 months (n=4364) and/or at 6 months (n=3148) were included. Prevalent AITD was defined as prescription of thyroxin substitution before RA-diagnosis (n=347), based on linkage to the Swedish Prescribed Drug register, and excluding participants with prescriptions for iodine-containing drugs or history of thyroid cancer (e.g. non-autoimmune cause of thyroxin use). We used a case-control design with thyroxin substitution as exposure, cases defined as EULAR DAS28 3- and 6-month non-responders, and controls defined as moderate/good responders at these time-points. Odds Ratios (OR) were calculated adjusted for sex, age, and HAQ. <h3>Results</h3> At 3 months, the proportion of thyroxin users did not differ between responders and non-responders 12% vs. 11%, (OR non-response =1.1, 95% CI 0.9–1.4). At 6 months, the corresponding figures were 13% vs. 11%, respectively, (OR non-response =1.3, 95% CI 1.0–1.7). However, a significant difference was observed in RF and/or ACPA positive patients at 6 months, where 15% of non-responders and 10% of responders used thyroxin (OR non-response=1.6, 95% CI 1.1–2.1), while no such difference was observed for seronegative RA. When stratified for gender, thyroxin substitution was significantly associated with non-response in men but not in women. <h3>Conclusions</h3> This large real-life study of response to methotrexate in early RA suggests that AITD, measured as thyroxin replacement therapy, may be linked to treatment response in seropositive patients (and among males). Exploratory by nature, these findings call for replication. <h3>Disclosure of Interest</h3> K. Waldenlind: None declared, S. Saevarsdottir: None declared, C. Bengtsson: None declared, J. Askling Grant/research support from: Abbvie, Pfizer, Lilly, Samsung, MSD, UCB, Roche, Janssen
Listen to Your Body
Authors: Carol Snyder Halberstadt
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Composite Biomarker Panel in Prediction of Severity and Diagnosis of Acute GvHD with T- Depleted Allogeneic Stem Cell Transplants- Single Centre Pilot Study
Authors: San San Min, Varun Mehra, Jennifer Clay, Gemma Cross, Abdel Douiri, Tracy Dew, Victoria T Potter, Tanya Basu, Roy Sherwood, Royce Vincent, M. Mansour Ceesay, Antonio Pagliuca
Journal: Blood (2016)
Are expanding disease definitions unnecessarily labelling women with polycystic ovary syndrome?
Authors: Tessa Copp, Jesse Jansen, Jenny Doust, Ben WJ Mol, Anuja Dokras, Kirsten McCaffery
Journal: BMJ (2017)

Since polycystic ovary syndrome was described in the 1930s, the diagnostic criteria have expanded and prevalence has risen, explain <b>Tessa Copp and colleagues</b>. But to what extent do women today benefit from their diagnosis, particularly younger women and those with milder symptoms?
生理活性リン酸三カルシウム移植片を用いたヒト頭蓋顔面骨再生に及ぼす性ホルモンレベル、性別、ボディマスインデックスと他の宿主因子の影響【Powered by NICT】
Authors: Knabe Christine, Mele Aynur, Kann Peter Herbert, Peleska Barbara, Adel-Khattab Doaa, Renz Harald, Reuss Alexander, Bohner Marc, Stiller Michael
Journal: Biomaterials (2017)
精密医療:時空間的ゲノム構造を明らかにすることで神経膠芽腫のプレシジョン・オンコロジーに関する情報が得られる
Authors: Lee Jin‐Ku, Lee In‐Hee, Kang Hyun Ju, Jung Sang Won, Choi Seung Won, Kim Junhyung, Shin Sang, Seo Yun Jee, OH Jin‐Mi, Shin Yong Jae, Nam Do‐Hyun, Kong Doo‐Sik, Seol Ho Jun, Lee Jung‐Il, Wang Jiguang, Ladewig Erik, Rosenbloom Daniel S, Camara Pablo G, Liu Zhaoqi, Van Nieuwenhuizen Patrick, Chen Andrew, Rabadan Raul, Park Woong‐Yang, Lee Hae‐Ock, Kim Kyu‐Tae, Park Chul‐Kee, Blumberg Andrew, Iavarone Antonio
Journal: Nature Genetics (2017)
Effect of Carcinogens on Small Free-Living Organisms II. Survival Value of Methylcholanthrene-adapted Paramecium
Authors: R. R. Spencer, M. B. Melroy
Journal: JNCI Journal of the National Cancer Institute (1940)

Journal Article Effect of Carcinogens on Small Free-Living Organisms II. Survival Value of Methylcholanthrene-adapted Paramecium Get access R. R. Spencer, R. R. Spencer assistant chief National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar M. B. Melroy M. B. Melroy assistant bacteriologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 3, December 1940, Pages 343–348, https://doi.org/10.1093/jnci/1.3.343 Published: 01 December 1940
Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial
Authors: Li Jiao, Liang Chen, Donna L White, Lesley Tinker, Rowan T Chlebowski, Linda V Van Horn, Peter Richardson, Dorothy Lane, Haleh Sangi-Haghpeykar, Hashem B El-Serag
Journal: JNCI Journal of the National Cancer Institute (2017)

Observational studies suggest that diet may influence pancreatic cancer risk. We investigated the effect of a low-fat dietary intervention on pancreatic cancer incidence. The Women's Health Initiative Dietary Modification (WHI-DM) trial is a randomized controlled trial conducted in 48 835 postmenopausal women age 50 to 79 years in the United States between 1993 and 1998. Women were randomly assigned to the intervention group (n = 19 541), with the goal of reducing total fat intake and increasing intake of vegetables, fruits, and grains, or to the usual diet comparison group (n = 29 294). The intervention concluded in March 2005. We evaluated the effect of the intervention on pancreatic cancer incidence with the follow-up through 2014 using the log-rank test and multivariable Cox proportional hazards regression model. All statistical tests were two-sided. In intention-to-treat analyses including 46 200 women, 92 vs 165 pancreatic cancer cases were ascertained in the intervention vs the comparison group (P = .23). The multivariable hazard ratio (HR) of pancreatic cancer was 0.86 (95% confidence interval [CI] = 0.67 to 1.11). Risk was statistically significantly reduced among women with baseline body mass indexes (BMIs) of 25 kg/m2 or higher (HR = 0.71, 95% CI = 0.53 to 0.96), but not among women with BMIs of less than 25 kg/m2 (HR = 1.62, 95% CI = 0.97 to 2.71, Pinteraction = .01). A low-fat dietary intervention was associated with reduced pancreatic cancer incidence in women who were overweight or obese in the WHI-DM trial. Caution needs to be taken in interpreting the findings based on subgroup analyses.
CD44過剰発現胃癌幹細胞治療のためのマイクロRNA‐34aのナノ小胞介在全身送達【Powered by NICT】
Authors: Jang Eunji, Kim Eunjung, Son Hye-Young, Lim Eun-Kyung, Lee Hwunjae, Choi Yuna, Park Kwangyeol, Han Seungmin, Suh Jin-Suck, Huh Yong-Min, Haam Seungjoo
Journal: Biomaterials (2016)
Maternal Antidepressant Use and Pregnancy Outcomes
Authors: Brian M. D’Onofrio, Ayesha C. Sujan
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
徐脈患者における新世代心房抗頻拍ペーシング(リアクティブATP)の有効性
Authors: Minamiguchi Hitoshi, Mizuno Hiroya, Ozu Kentaro, Konishi Shozo, Kioka Hidetaka, Ohtani Tomohito, Yamaguchi Osamu, Okuyama Yuji, Sakata Yasushi
Journal: Circulation (2016)
TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics
Authors: Ian R. Mackenzie, Alexandra M. Nicholson, Mohona Sarkar, James Messing, Maria D. Purice, Cyril Pottier, Kavya Annu, Matt Baker, Ralph B. Perkerson, Aishe Kurti, Billie J. Matchett, Tanja Mittag, Jamshid Temirov, Ging-Yuek R. Hsiung, Charles Krieger, Melissa E. Murray, Masato Kato, John D. Fryer, Leonard Petrucelli, Lorne Zinman, Sandra Weintraub, Marsel Mesulam, Julia Keith, Sasha A. Zivkovic, Veronica Hirsch-Reinshagen, Raymond P. Roos, Stephan Züchner, Neill R. Graff-Radford, Ronald C. Petersen, Richard J. Caselli, Zbigniew K. Wszolek, Elizabeth Finger, Carol Lippa, David Lacomis, Heather Stewart, Dennis W. Dickson, Hong Joo Kim, Ekaterina Rogaeva, Eileen Bigio, Kevin B. Boylan, J. Paul Taylor, Rosa Rademakers
Journal: Neuron (2017)
核エンベロープ障壁を乗越える:選択的CDK1抑制剤RO‐3306によるポリプレックス仲介性遺伝子のトランスフェクション効率の改善
Authors: Zhou Xuefei, Liu Xiangrui, Zhao Bingxiang, Liu Xin, Zhu Dingcheng, Qiu Nasha, Zhou Quan, Piao Ying, Zhou Zhuxian, Tang Jianbin, Shen Youqing
Journal: Journal of Controlled Release (2016)
Intraepithelial CD94+ tumor-infiltrating lymphocytes in a context of HLA-E overexpression as a new immune checkpoint to predict prognosis in colorectal carcinomas.
Authors: Celine Bossard, Juliette Eugene, Nicolas Jouand, Delphine Dansette, Edouard Leveque, Juliette Podevin, Tamara Matysiak, Stephane Bezieau, Jerome Chetritt, Olivier Kerdraon, Pierre Fourquier, Emilie Thibaudeau, Jean-François Mosnier, Anne Jarry, Nadine Gervois
Journal: Journal of Clinical Oncology (2017)

e14592 Background: A better understanding of the immune-modulating interactions between tumor cells and immune cells underlying the balance between immune control and immune resistance in colorectal cancer (CRC) is crucial for the design of immunotherapies. We have previously demonstrated that overexpression of the human MHC class Ib molecule - HLA-E/β2 microglobulin - by tumor cells in CRC was associated with an unfavorable prognosis, suggesting its involvement in immune escape. However, the specific receptor of HLA-E/β2m - CD94/NKG2A, inhibitory or CD94/NKG2C, activating - expressed by tumor-infiltrating lymphocytes (TIL), as well as the influence of the microsatellite status in HLA-E/β2m overexpression, remain unknown. Methods: We investigated in the primary tumor of 245 CRC patients 1) the association of HLA-E/β2m overexpression and the density of CD94 + intraepithelial TIL (IEL-TIL) with the microsatellite status, 2) the nature of CD94 + TIL and the receptor expressed - CD94/NKG2A or CD94/NKG2C - and 3) the prognostic influence of CD94 + IEL-TIL. Results: HLA-E/β2m was preferentially overexpressed in MSI compared with MSS CRC (44,6 % vs 18,4 % respectively, p = 0.0001), and significantly associated with a high density of CD94 + IEL-TIL in MSI (0,9% in HLA-E/β2m + vs 0,2% in HLA-E/β2m – CRC, p = 0,001), and in MSS CRC (0,38% vs 0,15%, p &lt; 0,0001). These CD94 + TIL mostly corresponded to CD8 + αβ T cells preferentially expressing the inhibitory NKG2A chain. Finally, a high density of CD94 + IEL-TIL was independently associated with a worse OS (p = 0.03). Conclusions: These results strongly suggest that HLA-E/β2m - CD94/NKG2A interactions, preferentially up-regulated in MSI CRC, represent a promising inhibitory immune checkpoint. From a clinical point of view, this inhibitory immune checkpoint could be blocked by the new anti-NKG2A monoclonal antibody.